Clinical Trials | December 03, 2025
Merck unveils first human data for Alzheimer’s candidates
The company also revealed that MK-2214 has received Fast Track Designation from the U.S. Food and Drug Administration
The company also revealed that MK-2214 has received Fast Track Designation from the U.S. Food and Drug Administration
The approvals target adult MIBC patients who are ineligible for cisplatin-based chemotherapy
This is the first and only subcutaneous immune checkpoint inhibitor available in Europe
The submissions are supported by data from the Phase 3 KEYNOTE-905 trial
The combination is approved for advanced endometrial carcinoma that is pMMR or not MSI-H and has progressed after prior systemic therapy
These findings follow positive Phase 3 results presented earlier this year
Merck will showcase results in innovative solutions in HIV treatment and prevention
The company will present new data from across over 20 cancer types and multiple treatment settings at European Society for Medical Oncology Congress 2025
Hyperion results presented at ERS 2025 and simultaneously published in the New England Journal of Medicine
Keytruda Qlex is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
